EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Opportunities for Therapeutic Modulation of O-GlcNAc

Steven S Cheng, Alison C Mody, Christina M Woo iD

Chemical Reviews · 27.11.2024 · 124 (22) · 12918-13019

DOI: 10.1021/acs.chemrev.4c00417 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemical Reviews, online erschienen am 07.11.2024. Verfasst von Steven S Cheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States. Hauptthemen laut MEDLINE: N-Acetylglucosaminyltransferases, Acetylglucosamine. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 1138 Literaturangaben. Gefördert von: NIA NIH HHS, Division of Chemistry, National Science Foundation Graduate Research Fellowship Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

O-Linked β-N-acetylglucosamine (O-GlcNAc) is an essential, dynamic monosaccharide post-translational modification (PTM) found on serine and threonine residues of thousands of nucleocytoplasmic proteins. The installation and removal of O-GlcNAc is controlled by a single pair of enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), respectively. Since its discovery four decades ago, O-GlcNAc has been found on diverse classes of proteins, playing important functional roles in many cellular processes. Dysregulation of O-GlcNAc homeostasis has been implicated in the pathogenesis of disease, including neurodegeneration, X-linked intellectual disability (XLID), cancer, diabetes, and immunological disorders. These foundational studies of O-GlcNAc in disease biology have motivated efforts to target O-GlcNAc therapeutically, with multiple clinical candidates under evaluation. In this review, we describe the characterization and biochemistry of OGT and OGA, cellular O-GlcNAc regulation, development of OGT and OGA inhibitors, O-GlcNAc in pathophysiology, clinical progress of O-GlcNAc modulators, and emerging opportunities for targeting O-GlcNAc. This comprehensive resource should motivate further study into O-GlcNAc function and inspire strategies for therapeutic modulation of O-GlcNAc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

N-AcetylglucosaminyltransferasesAcetylglucosamineHumansAnimalsbeta-N-AcetylhexosaminidasesEnzyme InhibitorsProtein Processing, Post-Translational

Substanzen

N-AcetylglucosaminyltransferasesO-GlcNAc transferaseAcetylglucosaminebeta-N-AcetylhexosaminidasesEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States.
  • Affiliate member of the Broad Institute, Cambridge, Massachusetts 02142, United States.

ORCID-Profile: Christina M Woo

Förderung

  • NIA NIH HHS
  • Division of Chemistry
  • National Science Foundation Graduate Research Fellowship Program
  • National Institute on Aging

Zitieren

APA

Cheng, S. S., Mody, A. C., & Woo, C. M. (2024). Opportunities for Therapeutic Modulation of O-GlcNAc. Chemical Reviews, 124(22), 12918-13019. https://doi.org/10.1021/acs.chemrev.4c00417

Vancouver

Cheng SS, Mody AC, Woo CM. Opportunities for Therapeutic Modulation of O-GlcNAc. Chemical Reviews. 2024;124(22):12918-13019. doi:10.1021/acs.chemrev.4c00417

BibTeX
@article{Cheng2024,
  author = {Cheng, Steven S and Mody, Alison C and Woo, Christina M},
  title = {Opportunities for Therapeutic Modulation of O-GlcNAc},
  journal = {Chemical Reviews},
  year = {2024},
  volume = {124},
  number = {22},
  pages = {12918--13019},
  doi = {10.1021/acs.chemrev.4c00417}
}
Kostenlos starten →